A Molecularly Detailed NaV1.5 Model Reveals a New Class I Antiarrhythmic Target

Jonathan D. Moreno, Wandi Zhu, Kathryn Mangold, Woenho Chung, Jonathan R. Silva

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Antiarrhythmic treatment strategies remain suboptimal due to our inability to predict how drug interactions with ion channels will affect the ability of the tissues to initiate and sustain an arrhythmia. We built a multiscale molecular model of the Na+ channel domain III (domain III voltage-sensing domain) to highlight the molecular underpinnings responsible for mexiletine drug efficacy. This model predicts that a hyperpolarizing shift in the domain III voltage-sensing domain is critical for drug efficacy and may be leveraged to design more potent Class I molecules. The model was therefore used to design, in silico, a theoretical mexiletine booster that can dramatically rescue a mutant resistant to the potent antiarrhythmic effects of mexiletine. Our framework provides a strategy for in silico design of precision-targeted therapeutic agents that simultaneously assesses antiarrhythmic markers of success and failure at multiple spatial and time scales. This approach provides a roadmap for the design of novel molecular-based therapy to treat myriad arrhythmia syndromes, including ventricular tachycardia, heart failure arrhythmias, and inherited arrhythmia syndromes.

Original languageEnglish
Pages (from-to)736-751
Number of pages16
JournalJACC: Basic to Translational Science
Issue number6
StatePublished - Oct 2019


  • arrhythmias
  • computational biology
  • ion channels
  • pharmacology
  • translational studies


Dive into the research topics of 'A Molecularly Detailed NaV1.5 Model Reveals a New Class I Antiarrhythmic Target'. Together they form a unique fingerprint.

Cite this